Varian closes acquisition of cancer treatment provider
Radiation therapy firm Varian Medical Systems has successfully acquired Cancer...Read more on AuntMinnie.comRelated Reading: Varian adds 2 interventional companies to roster Varian to acquire cancer treatment provider Varian completes ProBeam cyclotron install in Singapore Varian buys CyberHeart, wins Norwegian ProBeam contract Varian brings Bravos afterloader to Africa
Publication date: Available online 30 May 2020Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Renjie Wang, Zhengwei Cao, Lan Wei, Lin Bai, Hui Wang, Shiyi Zhou, Shuyue Zhan, Bin Ji, Zibo Li, Shi Gao, Jin Xie, Qingjie Ma
Conclusions: Hypothyroidism and difficult airways are a common sequel of RT. Selected cancer patients with subclinical hypothyroidism had a smooth perioperative course.
Conclusion: Conversion surgery offers benefits in terms of increase survival for initially UR-PDAC for patients who responded favorably to chemo(radiation)therapy when combined with postoperative adjuvant chemotherapy.
Conditions: Locally Advanced Rectal Carcinoma; Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v8; Stage IIA Rectal Cancer AJCC v8; Stage IIB Rectal Cancer AJCC v8; Stage IIC Rectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8; Stage IIIA Rectal Can cer AJCC v8; Stage IIIB Rectal Cancer AJCC v8; Stage IIIC Rectal Cancer AJCC v8 Inte...
Conclusions: Menopausal symptoms were prevalent in this population. Our data indicate that women are experiencing climacteric symptoms, but are overall unmotivated to address symptoms using HT. Factors such as symptom severity, fear of side effects, income level, or education level were not associated with acceptability of HT for premature menopause.
ConclusionsLow ‐dose hilar SBRT was efficacious and well‐tolerated, with impressive overall survival and no grade ≥ 3 toxicity. Repeat treatments with SBRT were feasible and effective, demonstrating overall survival, local control, and toxicity comparable to primary treatments.Key pointsSignificant findings of the study Low ‐dose hilar SBRT was efficacious and well‐tolerated Repeated treatments with SBRT demonstrated encouraging results, comparable to primary treatmentsWhat this study adds This study contributes to the small body of literature concerning hilar SBRT Repeat hilar SBRT was safe and fe...
ConclusionsIn our study, besides the known dosimetric factors, DM was found to be the most important risk factor causing RP development in multivariate analysis and RPA.The risk is tripled compared to patients without DM.
Abstract Perioperative chemotherapy has become a standard treatment for muscle invasive bladder cancer and is recommended by national and international guidelines. The treatment of metastatic urothelial cancer evolved by the use of immune-modulating therapies like checkpoint inhibitors. Many clinical trials have been initiated which try to evaluate the role of immune checkpoint inhibition in the neoadjuvant and adjuvant setting. These trials focus not only on monotherapy, but also on the combination of checkpoint inhibitors with classical chemotherapy or with local radiation therapy (radioimmunotherapy). In n...
Publication date: Available online 21 May 2020Source: Practical Radiation OncologyAuthor(s): Mark G. Trombetta, Anthony Dragun, Nina A. Mayr, Lori J. Pierce
Siemens Healthineers subsidiary PETNet Solutions and Zionexa have announced...Read more on AuntMinnie.comRelated Reading: ASTRO: Radiation therapy slashes breast cancer recurrence MRI + mammography detects recurrent breast cancer Blue Earth, PETNet expand Axumin distribution SNMMI: FDG-PET predicts breast cancer outcomes Blue Earth, PETNet roll out Axumin